Senti Biosciences (SNTI) said Monday that the first patient has been dosed in the pilot trial of SN301A to treat hepatocellular carcinoma.
The biotech firm said the trial, which is taking place in mainland China, is part of a collaboration with Celest Therapeutics.
Senti Bio said the two companies have the option to expand clinical development of SN301A to Hong Kong, Macau and Taiwan. It also said it will maintain all development and commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan.
Price: 5.21, Change: -0.36, Percent Change: -6.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。